Prevention of atrial fibrillation (AF) recurrence with anti-arrhythmic agents is generally
limited. Experimental studies suggest that angiotensin II receptor blockers (ARBs) can …

Background The possibility of preventing atrial fibrillation recurrence with anti-arrhythmic
agents is very limited, given the discouraging results obtained with current drugs in many …

Background Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy
is ideal for control of this condition. Experimental studies suggest that angiotensin II …

Atrial fibrillation (AF) is a very common arrhythmia. Currently available tools to control
arrhythmic recurrences (antiarrhythmic agents, catheter ablation) are not entirely …

How angiotensin inhibition might protect against AF is not completely known. There is a
plausible scientific basis for the notion that inhibition of the renin-angiotensin system can …

We thank Professors Celik and Iyisoy for their comments on the Candesartan in the
Prevention of Relapsing Atrial Fibrillation (CAPRAF) study [1]. This was the first double blind …

We could all learn from the Italian cardiologists. - Abstract - Europe PMC Sign in | Create an
account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us …

Atrial fibrillation (AF) is the most common sustained arrhythmia. While antiarrhythmic agents
and electrical cardioversion are highly effective in restoring sinus rhythm, the results …

Background—Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II
receptor blockade (ARB) in patients with structural heart disease is well established. The …

Purpose To analyze the published data on the role of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II-receptor blockers (ARBs) in secondary prevention of …